KLK2 and prostate carcinoma: PAI-1, one of the top dysregulated genes in this panel, was further validated across the panel of cancer cell lines and found to be upregulated in 12 of the 16 cell lines, the prostate cancer cell lines (PC-3 and LNCaP) being the exception, which may be related to the role of human kallikrein 2 which has been shown to inactivate PAI-1 in prostate cancer [42].